The NDA submission timeline (early Q4 2026) is the primary catalyst — monitor for filing confirmation and FDA acceptance. Cash runway through late Q4 2026 suggests a financing event may be needed before or alongside the NDA. The stock's reaction will hinge on regulatory progress rather than quarterly financials.
Price Chart
Executive Summary
Clene reported Q2 2026 results with a GAAP net loss of $13.4M ($1.08/share), significantly missing the $0.37 consensus due to non-cash fair value adjustments on warrant and derivative liabilities. The core operating loss narrowed slightly to $5.3M from $5.9M a year ago. The key catalyst is the planned NDA submission for CNM-Au8 in ALS under the accelerated approval pathway in early Q4 2026, supported by new biomarker data showing survival and functional benefit in patients with reduced neurofilament light (NfL). Cash of $9.7M provides runway through late Q4 2026, but the company will likely need additional financing.
Key Financial Metrics
Key Facts
- Plans to submit NDA for CNM-Au8 in ALS under accelerated approval pathway in early Q4 2026
- FDA confirmed proposed data may support NDA submission under accelerated approval
- New biomarker analyses show CNM-Au8-treated patients with stabilized/declining NfL lived significantly longer and had better function vs controls
- Q2 2026 total revenue $90K (up from $27K YoY), net loss $13.4M ($1.08/share) vs consensus $0.37 loss
- Cash and equivalents $9.7M as of June 30, 2026; operating cash burn $7.1M in H1 2026
- Closed $7.0M registered direct offering in May 2026; amended debt facilities to extend maturity to August 2027 and eliminate principal/interest payments before maturity
Financial Impact
Net loss of $13.4M in Q2 2026, driven by $8.1M in non-cash fair value losses on warrant and derivative liabilities; operating loss improved to $5.3M from $5.9M YoY
Risk Factors
- Cash runway only through late Q4 2026; additional financing likely required, potentially dilutive
- FDA may not accept the NDA or may require additional clinical data for accelerated approval
- Non-cash fair value adjustments create volatility in reported earnings; operating losses continue
- Low revenue base ($90K/quarter) with no approved products; commercialization timeline uncertain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345318 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $3.73 | awaiting T+20 | — | $3.88 (+4.02%) |
Oct 19, 2026 7d ago | 8-K | $3.29 | awaiting T+20 | — | $3.88 (+17.93%) |
Oct 19, 2026 7d ago | Press Release | $3.29 | awaiting T+20 | — | $3.88 (+17.93%) |
Oct 13, 2026 13d ago | SC 13G/A | $3.39 | awaiting T+20 | — | $3.88 (+14.45%) |
Sep 16, 2026 5w ago | 8-K | $4.15 $3.31 | ▲ +20.36% | ▲ +21.57% | $3.88 (+6.51%) |
Sep 16, 2026 5w ago | 424B5 | $3.86 $3.31 | ▲ +14.25% | ▲ +16.31% | $3.88 (−0.52%) |
Aug 14, 2026 10w ago | 8-K | $4.14 $3.28 | ▼ −20.77% | ▼ −18.78% | $3.88 (−6.28%) |
Aug 14, 2026 10w ago | Press Release | $4.14 $3.28 | ▼ −20.77% | ▼ −18.78% | $3.88 (−6.28%) |
Aug 10, 2026 11w ago | 8-K | $5.16 $3.62 | ▼ −29.84% | ▼ −28.93% | $3.88 (−24.81%) |
May 14, 2026 23w ago | 8-K | $7.05 $5.84 | ▼ −17.16% | ▼ −16.30% | $3.88 (−44.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers